Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | CASP3 | P42574 | 9/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 9/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 9/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 9/20 | 0.43 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | APP | P05067 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5542728 | 0.90 | CASP3 (0.52) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL5540542 | 0.89 | CASP3 (0.48) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL5545673 | 0.88 | CASP3 (0.47) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL5541758 | 0.87 | HSD17B10 (0.45) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL13273315 | 0.81 | SMN1; SMN2 (0.54) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL5545588 | 0.80 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL113955 | 0.80 | RAB9A (0.76) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL9016291 | 0.80 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL20178544 | 0.78 | NPC1 (0.46) | RAB9ANPC1SMN1; SMN2CASP3SENP8 | |
| SCHEMBL5538752 | 0.78 | HSD17B10 (0.43) | RAB9ANPC1SMN1; SMN2CASP3SENP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | RAB9A 2824/4885NPC1 2404/4885SMN1; SMN2 3985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.